Finding new compounds that activate a specific receptor related to hearing and balance.
Official title: Discovery of synthetic and endogenous ligands for orphan GPCR GPR156
Funded at University of Rochester · NIH-10987832 · Data updated 2026-11-12
This study is looking for new ways to help people with hearing and balance problems by finding substances that can activate a specific receptor in the body, which could lead to better treatments for these conditions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | August 15, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $659,164 |
| NIH project number | 1R01DC022104-01A1 |
| Project ID | NIH-10987832 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals experiencing hearing or balance disorders.
✕Less likely to help
Patients with conditions unrelated to hearing or balance disorders may not benefit from this research.
What this research studies
This research focuses on orphan G Protein Coupled Receptors (GPCRs), which are important for various physiological functions but lack known activating compounds. The team aims to discover both synthetic and natural ligands that can modulate the activity of GPR156, a receptor linked to hearing and balance disorders. Using advanced cell-based assays and innovative biosensor technologies, they will screen for potential ligands and validate their effects in relevant biological systems. This work could lead to new therapeutic options for patients with hearing and balance issues.
Why it matters
Potential benefit: If successful, this research could lead to the development of new treatments for hearing and balance disorders.
How similar studies have gone: Other research has shown promise in targeting orphan GPCRs, indicating potential for success in this novel approach.
Where this research is happening
-
University of Rochester
Rochester, United States Active
Researchers
- Principal investigator: Orlandi, Cesare — University of Rochester
- Study coordinator: Orlandi, Cesare
Related research
Other NIH-funded projects on the same topics.
-
Rapid automated breast lump diagnosis without a radiologist or sonographer
A new AI-powered ultrasound tool helps determine if a palpable breast lump is likely benign or malignant, using a simplified technique that can be used by people with minimal ultrasound training.
-
ML-ROVER: Reducing Unneeded Lab Tests in Kids with AI
Aims to use machine learning to cut unnecessary blood tests in children in intensive care, helping avoid anemia and improve care quality.
-
Aggressive fever-reducing therapy to protect the brains of children with CNS malaria
A study planned for children with CNS malaria will test whether aggressive fever-reducing treatment can lower death and brain-related problems.
-
Aggressive fever-reducing therapy to protect brains in children with CNS malaria
A plan to test whether giving strong fever-reducing medications to children with central nervous system malaria can lower death and brain injury.
-
Aggressive fever-fighting treatment to protect the brain in kids with CNS malaria
A plan to test whether giving strong fever-reducing treatment alongside standard care can lower death and brain injury in children with CNS malaria.
-
Aggressive fever-reducing treatment to protect brains in kids with CNS malaria
A plan to test whether giving strong fever-reducing medicine alongside standard malaria treatment can lower deaths and brain injuries in children with CNS malaria.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.